134 lines
4.8 KiB
Markdown
134 lines
4.8 KiB
Markdown
# CGM DMEPOS Market Research Synthesis — v1
|
|
Date: 2026-05-01
|
|
Source: Perplexity Deep Research (10 queries), internal review
|
|
|
|
## Purpose
|
|
Reference document for the Signal build-out. Corrects claims in existing
|
|
materials and establishes verified facts for all future copy, pitch docs,
|
|
and product positioning.
|
|
|
|
---
|
|
|
|
## Terminology (Confirmed)
|
|
|
|
Use "resupply" not "refill" in all materials.
|
|
CGM supply allowances (A4238/A4239) are exempt from Medicare refill
|
|
rules. DMEPOS suppliers process resupply orders, not prescriptions.
|
|
This distinction affects how Signal describes its workflow and how
|
|
supplier staff understands their obligations.
|
|
|
|
---
|
|
|
|
## Documentation Requirements (Confirmed)
|
|
|
|
Governing LCD: L33822 (Joint LCD — applies uniformly across all MACs)
|
|
|
|
Required for each CGM resupply claim:
|
|
- Valid order/prescription on file
|
|
- Face-to-face or telehealth qualifying visit within 6 months of
|
|
resupply (measured from last qualifying visit, not supply date)
|
|
- Supplier PECOS enrollment active and current
|
|
- SWO (Statement of Medical Necessity / Written Order) complete
|
|
- Proof of delivery (POD) on file
|
|
|
|
Note: POD is a top denial reason not in Signal's v1 scope.
|
|
Flag as a future module.
|
|
|
|
---
|
|
|
|
## Prior Authorization Status — April 2026
|
|
|
|
CGM HCPCS codes (A4238, A4239, K0553, K0554) are on the CMS Master
|
|
List of items requiring prior authorization consideration.
|
|
|
|
They are NOT on the Required Prior Authorization List as of April 2026.
|
|
|
|
Implication for Signal copy: do not frame PA as a current mandatory
|
|
burden for CGM. Frame it as a known future risk as CMS expands the
|
|
Required PA List. This is a compliance horizon item, not a present
|
|
obstacle.
|
|
|
|
---
|
|
|
|
## Verified Statistics (Use These. Retire the Others.)
|
|
|
|
| Claim | Status | Replace With |
|
|
|-------|--------|-------------|
|
|
| "94.2% of CGM denials are documentation failures" | NOT VERIFIABLE. Do not use. | See CERT data below |
|
|
| "35-45% of CGM claims denied" | Scenario-based, not universal. Qualify if used. | "first-pass denial rates vary significantly by supplier documentation maturity" |
|
|
| CERT 2019: 32.8% error rate for glucose monitors | Verified, CMS-sourced | Use with citation year |
|
|
| CERT 2019: 68.6% of those errors from insufficient documentation | Verified, CMS-sourced | Pair with above |
|
|
|
|
Recommended framing for Signal materials:
|
|
"CMS CERT data shows 32.8% of glucose monitor claims had errors,
|
|
with insufficient documentation driving over two-thirds of those
|
|
failures."
|
|
|
|
---
|
|
|
|
## Competitive Bidding 2028 (Confirmed)
|
|
|
|
Final rule: CMS-1828-F
|
|
Effective: January 1, 2028
|
|
CGMs explicitly included in the competitive bidding program.
|
|
|
|
Implication: small and mid-size suppliers face margin compression
|
|
and potential market exit if they cannot demonstrate clean claim rates
|
|
and operational efficiency before the bid cycle. This is Signal's
|
|
existential urgency driver for the 2026-2027 sales window.
|
|
|
|
---
|
|
|
|
## PECOS Validation — Genuine Signal Differentiator
|
|
|
|
Most billing platforms validate PECOS enrollment at intake (one time).
|
|
NikoHealth performs monthly automated PECOS checks per patient.
|
|
Most platforms do not.
|
|
|
|
Signal's per-resupply PECOS validation (each CSV import cycle) is
|
|
a differentiator. Suppliers whose PECOS lapses mid-cycle generate
|
|
denials with no warning under current workflows. Signal flags this
|
|
before the claim is submitted.
|
|
|
|
---
|
|
|
|
## Competitive Landscape — Key Finding
|
|
|
|
NikoHealth (~$3.5M revenue, independent): integration partner,
|
|
not competitor. Operates an AI-friendly billing hub with Tennr,
|
|
CompliantRx, and Notable. Signal complements this stack by
|
|
providing upstream documentation readiness that feeds cleaner
|
|
data into billing workflows.
|
|
|
|
Do not position Signal against NikoHealth. Position Signal as
|
|
what makes NikoHealth's workflow cleaner on the front end.
|
|
|
|
---
|
|
|
|
## HIPAA-Compliant Outreach Resources for Suppliers
|
|
|
|
Suppliers conducting outreach to prescribers and patients have
|
|
access to:
|
|
- Secure fax (still dominant in prescriber communication)
|
|
- HIPAA-compliant messaging platforms (Spruce Health, RingCentral
|
|
for Healthcare, Updox)
|
|
- EHR messaging via integration (limited by prescriber EHR access)
|
|
- Phone outreach with HIPAA-compliant call logging
|
|
|
|
Signal's role: identify who needs outreach and what is missing.
|
|
Selection of outreach channel remains with the supplier.
|
|
Signal does not recommend or integrate a specific outreach tool
|
|
in v1 scope.
|
|
|
|
---
|
|
|
|
## What This Changes in Existing Materials
|
|
|
|
| Document | Required Change |
|
|
|----------|----------------|
|
|
| pitch/master-summary.md | Replace 94.2% with CERT stat; qualify denial rate |
|
|
| pitch/signal-pitch-v1-plain.md | Same stat corrections; update product name |
|
|
| pitch/signal-pitch-v2-professional.md | Same stat corrections; update product name |
|
|
| sttil-website/signal-cgm.html | Same stat corrections; update product framing |
|
|
| pitch/signal-business-model-v1.md | PA section: reframe as future risk |
|
|
| KG: denial_root_cause | Correct "94 percent" fact (pending approval) |
|